Kim, Byung-Su
Chung, Pil-Wook
Kim, Byung-Kun
Lee, Mi Ji
Park, Jeong Wook
Chu, Min Kyung
Ahn, Jin-Young
Bae, Dae Woong
Song, Tae-Jin
Sohn, Jong-Hee
Oh, Kyungmi
Kim, Daeyoung
Kim, Jae-Moon
Kim, Soo-Kyoung
Choi, Yun-Ju
Chung, Jae Myun
Moon, Heui-Soo
Chung, Chin-Sang
Park, Kwang-Yeol
Cho, Soo-Jin http://orcid.org/0000-0002-4053-3763
Article History
Received: 18 January 2020
Accepted: 28 April 2020
First Online: 29 May 2020
Ethics approval and consent to participate
: The study protocol was approved by the ethics committee in each participating hospital and complied with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients fully understood the study aims and gave informed written consent before their participation.
: not applicable.
: Drs. BS Kim, PW Chung, BK Kim, MJ Lee, JW Park, JY Ahn, DW Bae, TJ Song, JH Sohn, K Oh, D Kim, JM Kim, SK Kim, YJ Choi, JM Chung, HS Moon, CS Chung, and KY Park report no conflict of interest.Dr. Chu was involved as a site investigator for a multicenter trial sponsored by Otsuka Korea, Allergan, Ildong Pharmaceutical Co., LTD, Novartis International AG, and Eli Lilly and Company. He worked an advisory member for Teva, and received lecture honoraria from Allergan Korea, Handok-Teva and Yuyu Pharmaceutical Company in the past 24 months.Dr. Cho was involved as a site investigator of multicenter trial sponsored Otsuka Korea, Allergan, Ildong Pharmaceutical Co., LTD, Novartis International AG, Eli Lilly and Company. Parexel Korea Co., Ltd., and and received lecture honoraria from Allergan Korea, WhanIn Pharm Co., LTD, Handok-Teva and Yuyu Pharmaceutical Company.